Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
Jesús F
JF
San-Miguel
D016588:Anticarcinogenic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
D016588:Anticarcinogenic Agents; D007155:Immunologic Factors; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide